Article
The KRAS mutational spectrum and its clinical implications in pancreatic cancer.
Cancer cell - 9 Sept 2024
Perelli Luigi, Genovese Giannicola, Draetta Giulio F
Abstract excerpt
In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRASG12R mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.
Topics
Join the communities discussing this publication.